Pfizer Basic EPS 2010-2024 | PFE

Pfizer annual/quarterly basic eps history and growth rate from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
  • Pfizer basic eps for the quarter ending September 30, 2024 was $0.79, a 288.1% decline year-over-year.
  • Pfizer basic eps for the twelve months ending September 30, 2024 was $0.76, a 58.92% decline year-over-year.
  • Pfizer annual basic eps for 2023 was $0B, a 93.2% decline from 2022.
  • Pfizer annual basic eps for 2022 was $0.006B, a 42.6% increase from 2021.
  • Pfizer annual basic eps for 2021 was $0.004B, a 137.58% increase from 2020.
Pfizer Annual Basic EPS
2023 $0.38
2022 $5.59
2021 $3.92
2020 $1.65
2019 $2.88
2018 $1.90
2017 $3.57
2016 $1.18
2015 $1.13
2014 $1.44
2013 $3.23
2012 $1.96
2011 $1.28
2010 $1.03
2009 $1.23
Pfizer Quarterly Basic EPS
2024-09-30 $0.79
2024-06-30 $0.01
2024-03-31 $0.55
2023-12-31 $-0.59
2023-09-30 $-0.42
2023-06-30 $0.41
2023-03-31 $0.98
2022-12-31 $0.88
2022-09-30 $1.54
2022-06-30 $1.77
2022-03-31 $1.40
2021-12-31 $0.61
2021-09-30 $1.45
2021-06-30 $0.99
2021-03-31 $0.87
2020-12-31 $0.16
2020-09-30 $0.26
2020-06-30 $0.63
2020-03-31 $0.60
2019-12-31 $-0.10
2019-09-30 $1.38
2019-06-30 $0.91
2019-03-31 $0.69
2018-12-31 $-0.06
2018-09-30 $0.70
2018-06-30 $0.66
2018-03-31 $0.60
2017-12-31 $2.05
2017-09-30 $0.48
2017-06-30 $0.52
2017-03-31 $0.52
2016-12-31 $0.13
2016-09-30 $0.22
2016-06-30 $0.34
2016-03-31 $0.49
2015-12-31 $-0.03
2015-09-30 $0.35
2015-06-30 $0.43
2015-03-31 $0.38
2014-12-31 $0.20
2014-09-30 $0.42
2014-06-30 $0.46
2014-03-31 $0.36
2013-12-31 $0.46
2013-09-30 $0.39
2013-06-30 $2.00
2013-03-31 $0.38
2012-12-31 $0.85
2012-09-30 $0.43
2012-06-30 $0.44
2012-03-31 $0.24
2011-12-31 $0.19
2011-09-30 $0.48
2011-06-30 $0.33
2011-03-31 $0.28
2010-12-31 $0.36
2010-09-30 $0.11
2010-06-30 $0.31
2010-03-31 $0.25
2009-12-31 $0.05
2009-09-30 $0.43
2009-06-30 $0.34
2009-03-31 $0.41
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $151.422B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51